Matthew Emmens, chief executive officer of Vertex Pharmaceuticals Inc., talks with Bloomberg's Julie Hyman about the outlook for the company's experimental hepatitis C treatment, in development with Johnson & Johnson, called telaprevir.
k
A study found that telaprevir worked in patients with hepatitis C who didn’t respond to other treatment. No proven medicines are available for hepatitis C patients who don’t respond to standard care.
k
(Source: Bloomberg)
Sept. 8 (Bloomberg) --http://www.clipsyndicate.com/video/play/1682082
No comments:
Post a Comment